Research ExplorerPublicationsPrognostic and predictive impact of soluble epidermal growth...

Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.

Standard

Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. / Müller, Volkmar; Witzel, Isabell; Pantel, Klaus; Krenkel, Sylke; Lück, Hans Joachim; Neumann, Rainer; Keller, Thomas; Dittmer, Jürgen; Jänicke, Fritz; Thomssen, Christoph.

In: ANTICANCER RES, Vol. 26, No. 2, 2, 2006, p. 1479-1487.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Müller, V, Witzel, I, Pantel, K, Krenkel, S, Lück, HJ, Neumann, R, Keller, T, Dittmer, J, Jänicke, F & Thomssen, C 2006, 'Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.', ANTICANCER RES, vol. 26, no. 2, 2, pp. 1479-1487. <http://www.ncbi.nlm.nih.gov/pubmed/16619561?dopt=Citation>

APA

Müller, V., Witzel, I., Pantel, K., Krenkel, S., Lück, H. J., Neumann, R., Keller, T., Dittmer, J., Jänicke, F., & Thomssen, C. (2006). Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. ANTICANCER RES, 26(2), 1479-1487. [2]. http://www.ncbi.nlm.nih.gov/pubmed/16619561?dopt=Citation

Vancouver

Müller V, Witzel I, Pantel K, Krenkel S, Lück HJ, Neumann R et al. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. ANTICANCER RES. 2006;26(2):1479-1487. 2.

Bibtex

@article{696a679a8c55453ab7903988143ced12,
title = "Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.",
abstract = "BACKGROUND: A soluble fragment of the epidermal growth factor receptor (EGFR) extracellular domain (sEGFR) can be detected in the serum of cancer patients, but the role of sEGFR is still unclear. MATERIALS AND METHODS: Blood samples from patients receiving chemotherapy for metastatic breast cancer were collected before (n = 101) and after 3 courses of therapy (n=39). Levels of sEGFR and serum HER-2/neu extracellular domain (ECD) were determined by standardized ELISA. RESULTS: A higher percentage of cancer patients (15%) showed sEGFR values below 45ng/mL compared with control subjects (3%, p15 ng/mL) also showed a shorter overall survival than those with normal values for both parameters (7.1 versus 15.4 months, p=0.03). Again, this difference was higher in patients with estrogen receptor-positive tumors (4.6 versus 15.4 month, p",
author = "Volkmar M{\"u}ller and Isabell Witzel and Klaus Pantel and Sylke Krenkel and L{\"u}ck, {Hans Joachim} and Rainer Neumann and Thomas Keller and J{\"u}rgen Dittmer and Fritz J{\"a}nicke and Christoph Thomssen",
year = "2006",
language = "Deutsch",
volume = "26",
pages = "1479--1487",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

RIS

TY - JOUR

T1 - Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.

AU - Müller, Volkmar

AU - Witzel, Isabell

AU - Pantel, Klaus

AU - Krenkel, Sylke

AU - Lück, Hans Joachim

AU - Neumann, Rainer

AU - Keller, Thomas

AU - Dittmer, Jürgen

AU - Jänicke, Fritz

AU - Thomssen, Christoph

PY - 2006

Y1 - 2006

N2 - BACKGROUND: A soluble fragment of the epidermal growth factor receptor (EGFR) extracellular domain (sEGFR) can be detected in the serum of cancer patients, but the role of sEGFR is still unclear. MATERIALS AND METHODS: Blood samples from patients receiving chemotherapy for metastatic breast cancer were collected before (n = 101) and after 3 courses of therapy (n=39). Levels of sEGFR and serum HER-2/neu extracellular domain (ECD) were determined by standardized ELISA. RESULTS: A higher percentage of cancer patients (15%) showed sEGFR values below 45ng/mL compared with control subjects (3%, p15 ng/mL) also showed a shorter overall survival than those with normal values for both parameters (7.1 versus 15.4 months, p=0.03). Again, this difference was higher in patients with estrogen receptor-positive tumors (4.6 versus 15.4 month, p

AB - BACKGROUND: A soluble fragment of the epidermal growth factor receptor (EGFR) extracellular domain (sEGFR) can be detected in the serum of cancer patients, but the role of sEGFR is still unclear. MATERIALS AND METHODS: Blood samples from patients receiving chemotherapy for metastatic breast cancer were collected before (n = 101) and after 3 courses of therapy (n=39). Levels of sEGFR and serum HER-2/neu extracellular domain (ECD) were determined by standardized ELISA. RESULTS: A higher percentage of cancer patients (15%) showed sEGFR values below 45ng/mL compared with control subjects (3%, p15 ng/mL) also showed a shorter overall survival than those with normal values for both parameters (7.1 versus 15.4 months, p=0.03). Again, this difference was higher in patients with estrogen receptor-positive tumors (4.6 versus 15.4 month, p

M3 - SCORING: Zeitschriftenaufsatz

VL - 26

SP - 1479

EP - 1487

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 2

M1 - 2

ER -